I am a
Home I AM A Search Login

Papers of the Week


2022 Nov 05


Expert Opin Pharmacother

Advances in pharmacotherapy for rosacea: what is the current state of the art?

Authors

Dall'Oglio F, Nasca M R, Gerbino C, Micali G
Expert Opin Pharmacother. 2022 Nov 05:1-10.
PMID: 36330970.

Abstract

Rosacea is a chronic and relapsing facial dermatosis that encompasses a wide spectrum of clinical phenotypes (transient/persistent erythema, telangiectasias, papules/pustules, edema, phymatous changes, and ocular symptoms) often with uncomfortable symptoms such as flushing, pain, burning, edema, and dryness. Current pharmacological treatment includes topical agents, spanning from several conventional (azelaic acid, metronidazole, sodium sulfacetamide) to new ones (brimonidine, oxymetazoline, ivermectine, minocycline), and systemic agents (doxycycline 40 mg modified-release), all Food and Drug Administration approved.